लोड हो रहा है...
Investigational Immunotherapeutics for B-Cell Malignancies
The use of rituximab-based chemoimmunotherapy regimens has remarkably improved the response rates, long-term outcomes, and quality of life of patients with B-cell malignancies. However, a substantial number of patients exhibit either primary or acquired resistance to rituximab, which suggests that n...
में बचाया:
| में प्रकाशित: | J Clin Oncol |
|---|---|
| मुख्य लेखकों: | , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
American Society of Clinical Oncology
2010
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872311/ https://ncbi.nlm.nih.gov/pubmed/20048186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.8254 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|